Prospective Open-Label Study of 48-Week Subcutaneous Administration of Mepolizumab in Japanese Patients With Severe Eosinophilic Asthma
Journal of Allergy and Clinical Immunology - United States
doi 10.1016/j.jaci.2018.12.313
Full Text
Open PDFAbstract
Available in full text
Date
February 1, 2019
Authors
Publisher
Elsevier BV